Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
NCT03704298 · Kite, A Gilead Company · PHASE1 · terminated · last registry update 2024-06-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Development program terminated” | – | Registry record, Kite, A Gilead Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD19 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-25Results posted on the registry: Amgen, Inebilizumab (NCT04540497)
- 2025-05-25Also stopped (terminated): Memorial Sloan Kettering Cancer Center, Tafasitamab + Lenalidomide (NCT05788289)
- 2025-05-23Results posted on the registry: Massachusetts General Hospital, Blinatumomab (NCT02811679)
- 2025-05-23Also stopped (terminated): Massachusetts General Hospital, Blinatumomab (NCT02811679)
- 2025-05-18Results posted on the registry: Amgen, Blinatumomab (NCT04506086)
- 2025-05-18Also stopped (terminated): Amgen, Blinatumomab (NCT04506086)
- 2025-05-13Results posted on the registry: Michael Burke, Blinatumomab (NCT04556084)
- 2025-05-13Also stopped (terminated): Michael Burke, Blinatumomab (NCT04556084)
- 2025-05-04Results posted on the registry: Marcela V. Maus, M.D.,Ph.D., Anakinra + Axicabtagene Ciloleucel (NCT04150913)
- 2025-04-20Results posted on the registry: Memorial Sloan Kettering Cancer Center, Tafasitamab + Lenalidomide (NCT05788289)
- 2025-04-04Results posted on the registry: Incyte Corporation, tafasitamab + rituximab (NCT04680052)
- 2025-03-27Results posted on the registry: Vanderbilt-Ingram Cancer Center, Axicabtagene Ciloleucel + Cyclophosphamide (NCT05108805)
- 2025-03-18Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Blinatumomab + Reinduction-2 omission (NCT06882057)
- 2025-03-06Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Randomization + Blinatumomab + chemotherapy + Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone (NCT06860269)
- 2025-02-20Phase 3 first posted: Da, Yuwei, M.D., Blinatumomab (NCT06836973)
- 2025-01-30Results posted on the registry: ADC Therapeutics S.A., Loncastuximab Tesirine + Rituximab (NCT05144009)
- 2025-01-30Also stopped (terminated): ADC Therapeutics S.A., Loncastuximab Tesirine + Rituximab (NCT05144009)
- 2025-01-28Results posted on the registry: M.D. Anderson Cancer Center, Anakinra + Axicabtagene Ciloleucel (NCT04432506)
- 2025-01-08Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Blinatumomab (Group A) + Venetoclax (nonRand Group) (NCT06764238)
- 2024-12-27Results posted on the registry: Celgene, JCAR017 (NCT03484702)
- 2024-11-12Also stopped (withdrawn): University Health Network, Toronto, Cyclophosphamide + Fludarabine (NCT06003179)
- 2024-11-12Phase 3 first posted: Zhongming Qiu, Blinatumomab (NCT06684184)
- 2024-10-16Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Ipilimumab (NCT02879695)
- 2024-10-16Results posted on the registry: MorphoSys AG, Tafasitamab + Tafasitamab plus lenalidomide (NCT04134936)
- 2024-09-24Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT02003222)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision